FindMyKOL
Clinical trialNCT01138371CompletedObservational

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

NCT01138371 is an observational study sponsored by Emory University. As of 21 Nov 2026, it is completed. It studies Familial Hypercholesterolemia. The registry lists an enrollment of 8 participants at 1 site in 1 country. The registry lists a start date of 31 Mar 2011 and a primary completion date of 29 Feb 2012.

SponsorEmory University →Enrollment8Familial Hypercholesterolemia
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01138371
FieldValue
Registry IDNCT01138371
StatusCompleted
Study typeObservational study
Lead sponsorEmory University
Enrollment8
Registered sites1
Countries1
ConditionsFamilial Hypercholesterolemia
Start31 Mar 2011
Primary completion29 Feb 2012
Study completion31 Mar 2012
Last update posted17 Dec 2013

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to measure how LDL apheresis affects levels of inflammatory and cholesterol markers in human beings. The investigators will address this question by drawing pre- and post-LDL apheresis blood from patients who are undergoing this procedure. A secondary objective of this study is to learn how specific inflammatory markers behave in our blood in terms of time to rebound back to normal levels. The investigators will address this question by drawing post-LDL apheresis blood at predetermined time intervals.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site
  • Emory University Hospital

    Atlanta

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT01138371

Each answer restates registry values shown on this page.

What is NCT01138371?

NCT01138371 is an observational study sponsored by Emory University. It studies Familial Hypercholesterolemia.

Who leads NCT01138371?

The registry names Laurence Sperling, MD (principal investigator, Emory University) and Vimal Ramjee, MD (study director, Emory University) as overall officials.

Where does NCT01138371 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When did NCT01138371 end?

The registry lists a primary completion date of 29 Feb 2012 and a study completion date of 31 Mar 2012. The sponsor last updated the record on 17 Dec 2013.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.